Accueil・Liste d'Actions・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Fermé

SecteurSoins de santé

27.59 3.41

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.19

Max

27.59

Chiffres clés
By Trading Economics
Revenu	1.3M 2.9M
Ventes	-19M 177M
P/E Moyenne du Secteur	207.077 68.51
BPA	0.6
Marge bénéficiaire	1.644
Employés	825
EBITDA	5M 30M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+17.64% upside

Dividendes
By Acuity
Prochains Résultats	5 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-40M 1.1B
Ouverture précédente	24.18
Clôture précédente	27.59

Sentiment de l'Actualité

By Acuity

50%

175 / 340 Classement par Healthcare

Pacira Pharmaceuticals Inc-DE Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 août 2026, 19:53 UTC

Pacira Biosciences Inc is higher today, supported by overall market strength and a decline in crude oil prices easing inflation concerns.

3 août 2026, 20:06 UTC

Pacira Biosciences Inc. shares are higher today, reflecting broader market gains led by major stocks, despite no specific company news identified.

31 juil. 2026, 20:02 UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

30 juil. 2026, 17:16 UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

29 juil. 2026, 20:04 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

28 juil. 2026, 19:56 UTC

Event

News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

27 juil. 2026, 18:51 UTC

Event

News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

24 juil. 2026, 17:16 UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

22 juil. 2026, 18:06 UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

21 juil. 2026, 19:56 UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

20 juil. 2026, 19:46 UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Comparaison

Variation de prix

Pacira Pharmaceuticals Inc-DE prévision

Objectif de Prix

By TipRanks

17.64% hausse

Prévisions sur 12 Mois

Moyen 31.67 USD 17.64%

Haut 38 USD

Bas 25 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

175 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.